IMAGING AGENTS FOR BETA CELL MASS OF PANCREAS

胰腺 β 细胞团显像剂

基本信息

  • 批准号:
    8052716
  • 负责人:
  • 金额:
    $ 31.73万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-04-01 至 2014-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Diabetes mellitus is a major metabolic disease with increasing significance. There are at least 20 million diabetic patients in the United States. Beta islet cells, which are the cells responsible for secreting insulin, play an important role in diabetes. Preserving or reversing the decline of beta cell mass (BCM) is one of the major goals for the treatment of diabetes. Measuring BCM in the pancreas by in vivo imaging will provide urgently needed information to understand the pathophysiology of diabetes and assist the development of new drug treatments. The objective of this proposal is to develop 18F labeled (+)-dihydrotetrabenazine ([18F](+)-DTBZ) derivatives to study vesicular monoamine transporter 2 (VMAT2) binding sites on the beta cells by positron emission tomography (PET) imaging. Recent reports suggested that [11C]DTBZ, a VMAT2 selective agent used in the diagnosis of Parkinson's disease, also showed promise for mapping the BCM of human pancreas by in vivo PET imaging. However, the short half-life (20 min) of 11C limits its widespread application; therefore, we propose to develop its 18F derivatives with a longer half-life (110 min) and an improved pancreas targeting ability suitable for a widespread clinical application. Additional novel DTBZ derivatives containing an in vivo metabolizing group (epoxide) for faster liver and kidney excretion will be synthesized and radiolabeled. In vivo biodistribution will demonstrate the binding of VMAT2 in normal and streptozotocin-treated rats (model for diabetes). One of the 18F labeled DTBZ derivatives recently developed in our laboratory showed superior pancreas targeting and low background noise. The uptake in the pancreas of normal rats was > 5 %dose/g at 30 min after an iv injection and the uptake was blocked (>80%) by a pretreatment of a challenging dose of VMAT2 ligand, suggesting a competitive binding to the same VMAT2 binding sites. PET imaging studies of normal rats showed excellent images of the pancreas with outstanding contrast to the surrounding tissues or organs. On the basis of the exciting preliminary results, the proposed 18F labeled DTBZ derivatives may provide an excellent platform to search for optimal imaging agents for beta cell mass (BCM). The proposed beta cell targeting PET imaging agents for measuring BCM in the pancreas are scientifically important and they may be useful for diagnosis and management of diabetic patients. PUBLIC HEALTH RELEVANCE: Diabetes mellitus is a major metabolic disease with increasing significance in the United States. Beta islet cells, which are the cells responsible for secreting insulin, play an important role in diabetes. Measuring beta cell mass (BCM) in the pancreas by in vivo imaging will provide critically useful information for diagnosis and management of diabetic patients.
描述(由申请人提供):

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Hank F Kung其他文献

First-in-human study of PSMA-targeting agent, [18F]AlF-P16-093: dosimetry and initial evaluation in prostate cancer patients.
PSMA 靶向剂 [18F]AlF-P16-093 的首次人体研究:前列腺癌患者的剂量测定和初步评估。
  • DOI:
    10.1007/s00259-024-06596-y
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    9.1
  • 作者:
    Ruiyue Zhao;Miao Ke;Jie Lv;Shaoyu Liu;Yuheng Liu;Jing Zhang;Lifu Xu;Di Gu;Mingzhao Li;Chao Cai;Yong;Guohua Zeng;D. Alexoff;K. Ploessl;Lin Zhu;Hank F Kung;Xinlu Wang
  • 通讯作者:
    Xinlu Wang

Hank F Kung的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Hank F Kung', 18)}}的其他基金

IMAGING AGENTS FOR BETA CELL MASS OF PANCREAS
胰腺 β 细胞团显像剂
  • 批准号:
    7781545
  • 财政年份:
    2010
  • 资助金额:
    $ 31.73万
  • 项目类别:
IMAGING AGENTS FOR BETA CELL MASS OF PANCREAS
胰腺 β 细胞团显像剂
  • 批准号:
    8310307
  • 财政年份:
    2010
  • 资助金额:
    $ 31.73万
  • 项目类别:
IMAGING AGENTS FOR BETA CELL MASS OF PANCREAS
胰腺 β 细胞团显像剂
  • 批准号:
    8255583
  • 财政年份:
    2010
  • 资助金额:
    $ 31.73万
  • 项目类别:
IMAGING AGENTS FOR BETA CELL MASS OF PANCREAS
胰腺 β 细胞团显像剂
  • 批准号:
    8462596
  • 财政年份:
    2010
  • 资助金额:
    $ 31.73万
  • 项目类别:
In vivo imaging agents targeting Tau aggregates
靶向 Tau 聚集体的体内成像剂
  • 批准号:
    7477147
  • 财政年份:
    2007
  • 资助金额:
    $ 31.73万
  • 项目类别:
In vivo imaging agents targeting Tau aggregates
靶向 Tau 聚集体的体内成像剂
  • 批准号:
    7329991
  • 财政年份:
    2007
  • 资助金额:
    $ 31.73万
  • 项目类别:
New imaging agents for studying gene expression
用于研究基因表达的新型成像剂
  • 批准号:
    7093967
  • 财政年份:
    2006
  • 资助金额:
    $ 31.73万
  • 项目类别:
New imaging agents for studying gene expression
用于研究基因表达的新型成像剂
  • 批准号:
    7230205
  • 财政年份:
    2006
  • 资助金额:
    $ 31.73万
  • 项目类别:
Imaging agents of norepinephrine transporters
去甲肾上腺素转运蛋白显像剂
  • 批准号:
    6923542
  • 财政年份:
    2005
  • 资助金额:
    $ 31.73万
  • 项目类别:
Imaging agents of norepinephrine transporters
去甲肾上腺素转运蛋白显像剂
  • 批准号:
    7009600
  • 财政年份:
    2005
  • 资助金额:
    $ 31.73万
  • 项目类别:

相似海外基金

Deep Learning prediction of pancreatic Beta cell transcription factor binding site using Cap analysis gene expression sequencing data
使用 Cap 分析基因表达测序数据深度学习预测胰腺 Beta 细胞转录因子结合位点
  • 批准号:
    558422-2020
  • 财政年份:
    2020
  • 资助金额:
    $ 31.73万
  • 项目类别:
    Canadian Graduate Scholarships Foreign Study Supplements
Analysis of the Role of Post-Transcriptional Regulation by the Poly(C) Binding Proteins in Pancreatic Beta Cell Homeostasis
聚 (C) 结合蛋白转录后调节在胰腺 β 细胞稳态中的作用分析
  • 批准号:
    10213016
  • 财政年份:
    2019
  • 资助金额:
    $ 31.73万
  • 项目类别:
Analysis of the Role of Post-Transcriptional Regulation by the Poly(C) Binding Proteins in Pancreatic Beta Cell Homeostasis
聚 (C) 结合蛋白转录后调节在胰腺 β 细胞稳态中的作用分析
  • 批准号:
    10020171
  • 财政年份:
    2019
  • 资助金额:
    $ 31.73万
  • 项目类别:
The role of PDZ binding kinase in beta cell proliferation during pregnancy
PDZ结合激酶在妊娠期β细胞增殖中的作用
  • 批准号:
    17K09846
  • 财政年份:
    2017
  • 资助金额:
    $ 31.73万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigating the Role of PHIP (Pleckstrin Homology Domain Binding Interacting Protein)in Beta-cell Function
研究 PHIP(Pleckstrin 同源结构域结合相互作用蛋白)在 β 细胞功能中的作用
  • 批准号:
    225398
  • 财政年份:
    2011
  • 资助金额:
    $ 31.73万
  • 项目类别:
    Studentship Programs
RNA Binding Proteins and Beta-cell Function
RNA 结合蛋白和 β 细胞功能
  • 批准号:
    6741671
  • 财政年份:
    2004
  • 资助金额:
    $ 31.73万
  • 项目类别:
RNA Binding Proteins and Beta-cell Function
RNA 结合蛋白和 β 细胞功能
  • 批准号:
    6943948
  • 财政年份:
    2004
  • 资助金额:
    $ 31.73万
  • 项目类别:
IGF binding protein-3 in beta cell apoptosis
IGF 结合蛋白 3 在 β 细胞凋亡中的作用
  • 批准号:
    6773831
  • 财政年份:
    2001
  • 资助金额:
    $ 31.73万
  • 项目类别:
IGF binding protein-3 in beta cell apoptosis
IGF 结合蛋白 3 在 β 细胞凋亡中的作用
  • 批准号:
    6605903
  • 财政年份:
    2001
  • 资助金额:
    $ 31.73万
  • 项目类别:
IGF binding protein-3 in beta cell apoptosis
IGF 结合蛋白 3 在 β 细胞凋亡中的作用
  • 批准号:
    6891873
  • 财政年份:
    2001
  • 资助金额:
    $ 31.73万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了